Unknown

Dataset Information

0

Sendai virus-based immunoadjuvant in hydrogel vaccine intensity-modulated dendritic cells activation for suppressing tumorigenesis.


ABSTRACT: The conventional immunoadjuvants in vaccine have weak effect on stimulating antigen presentation and activating anti-tumor immunity. Unexpectedly, we discovered that non-pathogenic Sendai virus (SeV) could activate antigen-presenting cells (APCs) represented by dendritic cells (DCs). Here, we designed an injectable SeV-based hydrogel vaccine (SHV) to execute multi-channel recruitment and stimulation of DCs for boosting the specific immune response against tumors. After the release of the NIR-triggered antigens from tumor cells, dendritic cells around the vaccine efficiently transport the antigens to lymph nodes and present them to T lymphocytes, thereby inducing systemic anti-tumor immune memory. Our findings demonstrated that the SHV with excellent universality, convenience and flexibility has achieved better immune protection effects in inhibiting the occurrence of melanoma and breast cancer. In conclusion, the SHV system might serve as the next generation of personalized anti-tumor vaccines with enhanced features over standard vaccination regimens, and represented an alternative way to suppress tumorigenesis.

SUBMITTER: Zheng B 

PROVIDER: S-EPMC8076650 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Sendai virus-based immunoadjuvant in hydrogel vaccine intensity-modulated dendritic cells activation for suppressing tumorigenesis.

Zheng Bin B   Peng Wenchang W   Gan Lin L   Guo Mingming M   Wang Shuchao S   Zhang Xiao-Dong XD   Ming Dong D  

Bioactive materials 20210413 11


The conventional immunoadjuvants in vaccine have weak effect on stimulating antigen presentation and activating anti-tumor immunity. Unexpectedly, we discovered that non-pathogenic Sendai virus (SeV) could activate antigen-presenting cells (APCs) represented by dendritic cells (DCs). Here, we designed an injectable SeV-based hydrogel vaccine (SHV) to execute multi-channel recruitment and stimulation of DCs for boosting the specific immune response against tumors. After the release of the NIR-tri  ...[more]

Similar Datasets

| S-EPMC7160722 | biostudies-literature
| S-EPMC5942581 | biostudies-literature
| S-EPMC8037748 | biostudies-literature
| S-EPMC8452861 | biostudies-literature
| S-EPMC8270077 | biostudies-literature
| S-EPMC5295430 | biostudies-literature
| S-EPMC236828 | biostudies-other
| S-EPMC5078770 | biostudies-literature
| S-EPMC6043750 | biostudies-other
| S-EPMC3799727 | biostudies-other